Cidara Therapeutics, Inc. (CDTX) financial statements (2021 and earlier)

Company profile

Business Address 6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36507575105108
Cash and cash equivalents365075618563
Short-term investments   151945
Restricted cash and investments710    
Receivables11  0  
Other undisclosed current assets363211
Total current assets:57667778105108
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment001112
Other noncurrent assets211000
Total noncurrent assets:332122
TOTAL ASSETS:60697979107110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities171010996
Accounts payable523333
Accrued liabilities844431
Employee-related liabilities443331
Debt711103  
Derivative instruments and hedges, liabilities  0   
Other undisclosed current liabilities1510    
Total current liabilities:3930201296
Noncurrent Liabilities
Long-term debt and lease obligation 1    
Operating lease, liability 1
Liabilities, other than long-term debt  0 00
Other liabilities  0 00
Other undisclosed noncurrent liabilities11  710 
Total noncurrent liabilities:11107100
Total liabilities:50312019196
Stockholders' equity
Stockholders' equity attributable to parent1138596088104
Common stock000000
Additional paid in capital345298278209182149
Accumulated other comprehensive loss   (0)(0)(0)
Accumulated deficit(335)(260)(219)(149)(94)(45)
Total stockholders' equity:1138596088104
TOTAL LIABILITIES AND EQUITY:60697979107110

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(84)(63)(63)(56)(48)(32)
Other undisclosed operating income1221    
Operating loss:(72)(42)(63)(56)(48)(32)
Nonoperating income (expense)(0)14(0)00
Other nonoperating income (expense)(0)14(0)0 
Interest and debt expense(0)(0)(0)(0)(0)(0)
Net loss:(72)(41)(59)(56)(48)(32)
Other undisclosed net income attributable to parent000000
Net loss attributable to parent:(72)(41)(59)(56)(48)(32)
Preferred stock dividends and other adjustments(3) (10)   
Net loss available to common stockholders, diluted:(75)(41)(69)(56)(48)(32)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(72)(41)(59)(56)(48)(32)
Comprehensive loss:(72)(41)(59)(56)(48)(32)
Other undisclosed comprehensive income, net of tax, attributable to parent000000
Comprehensive loss, net of tax, attributable to parent:(72)(41)(59)(56)(48)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: